Inspire Medical Systems, Inc. (INSP)
| Market Cap | 1.31B -65.1% |
| Revenue (ttm) | 915.25M +8.9% |
| Net Income | 131.14M +97.2% |
| EPS | 4.47 +106.4% |
| Shares Out | 28.81M |
| PE Ratio | 10.16 |
| Forward PE | 46.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,348,586 |
| Open | 45.21 |
| Previous Close | 44.61 |
| Day's Range | 45.21 - 47.10 |
| 52-Week Range | 38.91 - 147.03 |
| Beta | 0.71 |
| Analysts | Hold |
| Price Target | 51.77 (+13.88%) |
| Earnings Date | Aug 3, 2026 |
About INSP
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open ai... [Read more]
Financial Performance
In 2025, Inspire Medical Systems's revenue was $911.98 million, an increase of 13.60% compared to the previous year's $802.80 million. Earnings were $145.42 million, an increase of 171.77%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for INSP stock is "Hold." The 12-month stock price target is $51.77, which is an increase of 13.88% from the latest price.
News
Inspire Medical initiated with a Buy at Freedom Capital
Freedom Capital initiated coverage of Inspire Medical (INSP) with a Buy rating and $62 price target The neurostimulation market is an attractive growth opportunity where small-to-mid cap players like ...
Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its...
Inspire Medical Systems Transcript: Wells Fargo 2026 MedTech Innovation Spotlight
Clear coding and reimbursement pathways are now in place, with Inspire V showing improved clinical outcomes and strong patient adherence. New data links therapy to reduced cardiovascular risk, while ongoing innovation and market education support future growth.
Inspire Medical downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst Daniel Markowitz downgraded Inspire Medical (INSP) to In Line from Outperform with a price target of $40, down from $55. Since no permanent code accurately describes the…
Inspire Medical Systems, Inc. Announces Presence at SLEEP 2026 and Publication of PREDICTOR Study
Highlights New Clinical Data, Technology Advancements, and Cardiovascular Outcomes Research Highlights New Clinical Data, Technology Advancements, and Cardiovascular Outcomes Research
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2026 MedTech Innovation Spotlight
MINNEAPOLIS, June 12, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minima...
Inspire Medical downgraded to Underperform at BofA on coding overhang
BofA downgraded Inspire Medical (INSP) to Underperform from Neutral with a price target of $39, down from $53. The firm sees higher risk to estimates without a smooth and consistent…
Inspire Medical downgraded to Underperform from Neutral at BofA
BofA downgraded Inspire Medical (INSP) to Underperform from Neutral with a price target of $39, down from $53.
Inspire Medical Systems Transcript: Bank of America Global Healthcare Conference 2026
Cost discipline and patient outcomes remain central as coding changes and reimbursement challenges drive a temporary revenue decline, with Q2 expected as the low point. Sequential improvement is anticipated, supported by expanded education efforts and a focus on long-term solutions, while new product benefits and market adaptation are expected to drive gradual recovery.
Inspire Medical price target lowered to $50 from $64 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Inspire Medical (INSP) to $50 from $64 and keeps a Hold rating on the shares. The company has significantly cut…
Inspire Medical price target lowered to $54 from $67 at JPMorgan
JPMorgan lowered the firm’s price target on Inspire Medical (INSP) to $54 from $67 and keeps a Neutral rating on the shares. The firm materially cut estimates post the earnings…
Inspire Medical price target lowered to $55 from $62 at Evercore ISI
Evercore ISI lowered the firm’s price target on Inspire Medical (INSP) to $55 from $62 and keeps an Outperform rating on the shares.
Inspire Medical price target lowered to $45 from $56 at RBC Capital
RBC Capital lowered the firm’s price target on Inspire Medical (INSP) to $45 from $56 and keeps a Sector Perform rating on the shares. The company lowered its 2026 revenue…
Inspire Medical price target lowered to $55 from $70 at Mizuho
Mizuho lowered the firm’s price target on Inspire Medical (INSP) to $55 from $70 and keeps an Outperform rating on the shares.
Inspire Medical price target lowered to $65 from $70 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Inspire Medical (INSP) to $65 from $70 and keeps a Buy rating on the shares.
Piper downgrades Inspire Medical to Neutral on guidance cut
Piper Sandler downgraded Inspire Medical (INSP) to Neutral from Overweight with a price target of $55, down from $85. The stock in premarket trading is down 22%, or $12.04, to…
Inspire Medical price target lowered to $50 from $63 at Baird
Baird analyst David Rescott lowered the firm’s price target on Inspire Medical (INSP) to $50 from $63 and keeps a Neutral rating on the shares. The firm updated its model…
Inspire Medical downgraded at BofA on cloudy path back to growth
As previously reported, BofA downgraded Inspire Medical (INSP) to Neutral from Buy with a price target of $53, down from $120. While the firm still believes in Inspire’s product, acknowledges…
Inspire Medical Systems Earnings Call Transcript: Q1 2026
Revenue grew 1.6% to $204.6M in Q1 2026, but ongoing coding, reimbursement, and WISeR program headwinds led to a downward revision of full-year guidance. Adjusted operating income and cash flow improved, with sequential recovery expected in the second half as coding clarity increases.
Inspire Medical Systems Earnings release: Q1 2026
Inspire Medical Systems released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Inspire Medical Systems Quarterly report: Q1 2026
Inspire Medical Systems has published its Q1 2026 quarterly earnings report on May 4, 2026.
Inspire Medical Systems Slides: Q1 2026
Inspire Medical Systems has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 4, 2026.
Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of inn...
Inspire Medical Systems Transcript: AGM 2026
The meeting highlighted strong 2025 financial growth, key leadership changes, and approval of all seven shareholder proposals, including board structure reform and incentive plan amendments. Strategic innovation and governance enhancements were emphasized.
Inspire Medical Systems, Inc. to Present at the BofA Securities 2026 Healthcare Conference
MINNEAPOLIS, April 29, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minim...